3LT® Lasers

Worlds most researched 3LT® Lasers!

PL 5000
PL5000
Erchonia's patent-pending line of 3LT® Lasers is headed up by the PL5000. Completely redesigned to reflect the features and functions requested by the doctors and practitioners that have been using Erchonia 3LT® Lasers to treat their patients since 1996.

The PL5000 is a variable frequency, four diode laser that is encased in a custom designed, aircraft quality aluminum housing to resist the rigors of daily use in the real world. Ergonomically designed to fit hands of all sizes, the dual-diode head, conveniently clips to the side of the laser when not in use, which increases security and prevents accidental ocular exposure to both patient and doctor.

About the only mechanical piece on the PL5000 is the lock and key that enables the owner to prevent the unauthorized use of the laser.

PL 3000
PL3000
The PL3000 is a variable frequency (1hz-1,000hz), single diode 3LT® 635nm wavelength laser that is encased in a ergonomically designed, machine billet aluminum housing to resist the rigors of daily use in the real world. Designed to fit hands of all sizes, the single-diode head, conveniently clips to the side of the laser when not in use, which increases security and prevents accidental occular exposure to both patient and doctor.

 

Base Station™

Not only was Erchonia the first Low Level Laser to receive 510(k) market clearance from the FDA for Chronic Pain, Laser Assisted Liposuction, and now the treatment of Acne.  Erchonia is now offering all three lasers in one conveinient unit.  The Base Station™ is a perfect solution for the multiple room clinic.  It is a patented, desk top model; that houses three separate, cordelss, hand held units,
 All three units are programmed from one control station (the base) and operate independently, powered by their own internal battery source.  This is the ultimate in ergonomics, space savings and portability. 

 


LipoLASER™

Erchonia's patented line of 3LT®  Lasers now includes the FIRST and ONLY Low Level Laser (3LT®) to be given FDA market clearance for use during liposuction - the Erchonia LipoLASER™..

The painless laser treatment is administered a few minutes prior to liposuction and works by liquefying the fat. As a result, fat removal is made easier and quicker. There is less post-op pain and bruising and a speedier recovery time. In addition less pain medication is required.

We received market clearance on the LipoLASER™ based on the results of an IRB approved, multi-center, double blind, randomized study. The comparison between the actively treated patients and the placebo-treated patients resulted in an impressive difference between groups in degree of pain. Significant differences in emulsification of fat, ease of extraction, and amount of swelling were also recorded.

"This approval is a major step forward in our goal to establish the Erchonia LipoLASER™ as the future of liposuction," comments Charlie Shanks, VP of Sales and Marketing for Erchonia Medical. "We believe that eventually patients will demand laser-assisted liposuction over traditional methods because of the amazing post-operative benefits."

DermaLASER™
DermaLaser
The Erchonia DermaLASER™ is the FIRST and ONLY Low Level Laser (3LT®) to be given FDA market clearance for the treatment of acne.

The Erchonia DermaLASER™ is a low-level, or cold, laser that works by killing the bacteria P. Acnes that causes acne. Unlike current acne-laser treatments, the Erchonia DermaLASER™ is not high density, or hot, so it does not irritate or adversely affect the healthy skin cells. The Erchonia DermaLASER™ targets only the acne-causing bacteria itself, not the skin, so it effectively treats the cause of acne at its root.

Up until now, people with acne have had to rely on strong antibiotic treatments lasting several months, harsh topical ointments that can irritate and severely dry out the skin or hot lasers that cause redness and pain. 30 years of research shows that side affects from low-level laser treatments of all kinds are minimal to non-existent and the DermaLASER™ is no exception.

"This FDA market clearance is a major step forward in the fight against acne and the misery it causes teens and adults alike," comments Charlie Shanks, VP of Sales and Marketing for Erchonia Medical. "For the first time it is possible to painlessly and quickly treat the root causes of acne, instead of the usual symptomatic treatments of messy ointments and creams."